TerSera Therapeutics Revenue and Competitors

Claim your profile

Chicago, IL USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • TerSera Therapeutics's estimated annual revenue is currently $31M per year.(i)
  • TerSera Therapeutics's estimated revenue per employee is $201,000

Employee Data

  • TerSera Therapeutics has 154 Employees.(i)
  • TerSera Therapeutics grew their employee count by 6% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$69.5M346-3%N/AN/A
#2
$15.3M76-20%$35MN/A
#3
$4.2M21-5%N/AN/A
#4
$21.7M108-11%N/AN/A
#5
$12.7M63-10%N/AN/A
#6
$10.5M52-7%N/AN/A
#7
$14.3M71-4%N/AN/A
#8
$26.3M131-5%N/AN/A
#9
$200.6M9980%N/AN/A
#10
$18.7M93N/AN/AN/A

TerSera Therapeutics acquires and develops specialty pharmaceutical products with a focus on select therapeutic areas. Our mission is to market products which truly make a difference for patients. Our focus is to bring intelligent solutions to prescribers and patients who need better solutions. We deliver a comprehensive set of programs that go beyond the therapy itself in order to provide improved outcomes for patients.

keywords:N/A

N/A

Total Funding

154

Number of Employees

$31M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

TerSera Therapeutics News

08/29/2019 - Goserelin Market SWOT Analysis including key players ...

Goserelin Market SWOT Analysis including key players AstraZeneca, TerSera Therapeutics, Luye Pharma A Comprehensive Study exploring ...

09/04/2019 - Meloxicam Drug Market Latest Trend with Top key players ...

Meloxicam Drug Market Latest Trend with Top key players: Boehringer-Ingelheim, TerSera Therapeutics, Iroko Pharmaceuticals, Apotex, Yung ...

09/03/2019 - Plenty of Opportunities in Meloxicam Drug Market Studied in ...

Plenty of Opportunities in Meloxicam Drug Market Studied in Detail along with Top Companies as Boehringer-Ingelheim, TerSera Therapeutics, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$42.5M154-7%N/A
#2
$47.5M1700%N/A
#3
$48.1M1734%N/A
#4
$42.6M17627%N/A
#5
N/A1869%N/A